Login| Sign Up| Help| Contact|

Patent Searching and Data


Title:
APPLICATION OF NOVEL TYROSINE KINASE INHIBITOR, ANLOTINIB, IN OSTEOSARCOMA
Document Type and Number:
WIPO Patent Application WO/2019/140937
Kind Code:
A1
Abstract:
An application of anlotinib and a pharmaceutically acceptable salt thereof in the preparation of a drug which inhibits or treats osteosarcoma.

Inventors:
HUA YINGQI (CN)
WANG GANGYANG (CN)
CAI ZHENGDONG (CN)
WANG ZHUOYING (CN)
ZHANG TAO (CN)
WANG HONGSHENG (CN)
SUN MENGXIONG (CN)
Application Number:
PCT/CN2018/106625
Publication Date:
July 25, 2019
Filing Date:
September 20, 2018
Export Citation:
Click for automatic bibliography generation   Help
Assignee:
SHANGHAI GENERAL HOSPITAL (CN)
International Classes:
A61K31/4709; A61P35/00
Foreign References:
CN107970241A2018-05-01
CN101809012A2010-08-18
Other References:
GAO, TIAN ET AL.: "Advances in Molecular Targeted Therapy for Soft Tissue Sarcomas", CHINESE JOURNAL OF CLINICAL ONCOLOGY, vol. 44, no. 1, 31 January 2017 (2017-01-31), pages 9
LI, XIAOQIN ET AL.: "Expression of C-kit Receptor and Platelet-Derived Growth Factor Receptor-a in Osteosarcoma and their Significance", CHINESE JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, vol. 29, no. 8, 31 August 2013 (2013-08-31), pages 870
Attorney, Agent or Firm:
SHANGHAI ZHUOYANG INTELLECTUAL PROPERTY AGENT FIRM (CN)
Download PDF:



 
Previous Patent: GLASSES

Next Patent: BUSHING AND REMOTE CONTROL